Advanced Oncotherapy PLC’s (AVO) “Speculative Buy” Rating Reiterated at Beaufort Securities

Beaufort Securities reissued their speculative buy rating on shares of Advanced Oncotherapy PLC (LON:AVO) in a research note released on Monday morning.

Shares of Advanced Oncotherapy PLC (LON:AVO) opened at 106.10 on Monday. The company’s market cap is GBX 60.19 million. Advanced Oncotherapy PLC has a one year low of GBX 98.00 and a one year high of GBX 217.25. The firm has a 50-day moving average of GBX 118.61 and a 200 day moving average of GBX 145.19.

In other news, insider Bradfield ,Michael acquired 30,000 shares of the stock in a transaction on Monday, July 11th. The shares were purchased at an average price of GBX 135 ($1.76) per share, for a total transaction of £40,500 ($52,865.16).

About Advanced Oncotherapy PLC

Advanced Oncotherapy Plc is a United Kingdom-based company. The Company is engaged in providing medical technology for cancer treatment and managing a health-related property. The Company operates in three business segments: Proton Therapy, Single Dose Intra-Operative Radiotherapy Treatment (SDIORT) and Healthcare related properties.

Receive News & Ratings for Advanced Oncotherapy PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy PLC and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.